George Sam Wang1, Christine Buttorff2, Asa Wilks3, Daniel Schwam2, Gregory Tung4, Rosalie Liccardo Pacula5. 1. University of Colorado Anschutz Medical Campus Children's, Hospital Colorado Department of Pediatrics 13123 East 16th Ave B251 Aurora CO 80045, United States. Electronic address: george.wang@childrenscolorado.org. 2. RAND Corporation, 1200 S. Hayes St Arlington VA 22202, United States. 3. RAND Corporation, 1776 Main Street Santa Monica, CA 90407, United States. 4. University of Colorado Anschutz Medical Campus Colorado School of Public Health Department of Health Systems, Management & Policy Program for Injury Prevention, Education and Research (PIPER) Colorado School of Public Health, 13001 E. 17th Place, MS B119, United States. 5. University of Southern California Sol Price School of Public Policy, Schaeffer Center for Health Policy & Economics 635 Downey Way, VPD 514J, Los Angeles, CA 90089-3333, United States.
Abstract
BACKGROUND: Emergency department (ED) visits involving psychosis and schizophrenia have increased at a rate exceeding population growth in the United States over the past decade. Research shows a strong dose-response relationship between chronic use of high-potency cannabis and odds of developing symptoms of psychosis. The aim of this study was to evaluate the impact of cannabis legalization on psychosis and schizophrenia-related ED visits in Colorado. METHODS: Using administrative data from Colorado Hospital Association (CHA) on county-level quarterly ED visits between January 1, 2013, and December 31, 2018, we applied a difference-in-difference analysis to examine how new exposure to recreational cannabis dispensaries after 2014 differentially influenced the rate of ED visits for psychosis and schizophrenia, comparing counties with no prior medical cannabis dispensary exposure to counties with low or high medical dispensary exposure. RESULTS: As recreational dispensaries per 10,000 residents increased, there was no significant association with the rate of schizophrenia ED visits per capita (incidence rate ratio or IRR: 0.95, 95% CI [0.69, 1.30]) while the rate of psychosis visits increased 24% (IRR: 1.24, 95% CI [1.02, 1.49]). Counties with no previous medical dispensaries experienced larger increases in schizophrenia ED visits than counties already exposed to a low level of medical dispensaries, but this effect was not significant. Counties with low baseline medical exposure had lower increases in rates of psychosis visits than counties with high baseline medical exposure (IRR 0.83, 95% CI [0.69, 0.99]). CONCLUSIONS: There was a positive association between the number of cannabis dispensaries and rates of psychosis ED visits across all counties in Colorado. Although it is unclear whether it is access to products, or the types of products that may be driving this association, our findings suggest there is a potential impact on the mental health of the local population that is observed after cannabis legalization.
BACKGROUND: Emergency department (ED) visits involving psychosis and schizophrenia have increased at a rate exceeding population growth in the United States over the past decade. Research shows a strong dose-response relationship between chronic use of high-potency cannabis and odds of developing symptoms of psychosis. The aim of this study was to evaluate the impact of cannabis legalization on psychosis and schizophrenia-related ED visits in Colorado. METHODS: Using administrative data from Colorado Hospital Association (CHA) on county-level quarterly ED visits between January 1, 2013, and December 31, 2018, we applied a difference-in-difference analysis to examine how new exposure to recreational cannabis dispensaries after 2014 differentially influenced the rate of ED visits for psychosis and schizophrenia, comparing counties with no prior medical cannabis dispensary exposure to counties with low or high medical dispensary exposure. RESULTS: As recreational dispensaries per 10,000 residents increased, there was no significant association with the rate of schizophrenia ED visits per capita (incidence rate ratio or IRR: 0.95, 95% CI [0.69, 1.30]) while the rate of psychosis visits increased 24% (IRR: 1.24, 95% CI [1.02, 1.49]). Counties with no previous medical dispensaries experienced larger increases in schizophrenia ED visits than counties already exposed to a low level of medical dispensaries, but this effect was not significant. Counties with low baseline medical exposure had lower increases in rates of psychosis visits than counties with high baseline medical exposure (IRR 0.83, 95% CI [0.69, 0.99]). CONCLUSIONS: There was a positive association between the number of cannabis dispensaries and rates of psychosis ED visits across all counties in Colorado. Although it is unclear whether it is access to products, or the types of products that may be driving this association, our findings suggest there is a potential impact on the mental health of the local population that is observed after cannabis legalization.
Authors: George Sam Wang; Katelyn Hall; Daniel Vigil; Shireen Banerji; Andrew Monte; Mike VanDyke Journal: Prev Med Date: 2017-03-30 Impact factor: 4.018
Authors: Deepak Cyril D'Souza; Edward Perry; Lisa MacDougall; Yola Ammerman; Thomas Cooper; Yu-Te Wu; Gabriel Braley; Ralitza Gueorguieva; John Harrison Krystal Journal: Neuropsychopharmacology Date: 2004-08 Impact factor: 7.853
Authors: Shelby K Shelton; Eleanor Mills; Jessica L Saben; Michael Devivo; Kayla Williamson; Diana Abbott; Katelyn E Hall; Andrew A Monte Journal: Clin Toxicol (Phila) Date: 2019-09-16 Impact factor: 4.467
Authors: Marta Di Forti; Diego Quattrone; Tom P Freeman; Giada Tripoli; Charlotte Gayer-Anderson; Harriet Quigley; Victoria Rodriguez; Hannah E Jongsma; Laura Ferraro; Caterina La Cascia; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Andrei Szöke; Celso Arango; Andrea Tortelli; Eva Velthorst; Miguel Bernardo; Cristina Marta Del-Ben; Paulo Rossi Menezes; Jean-Paul Selten; Peter B Jones; James B Kirkbride; Bart Pf Rutten; Lieuwe de Haan; Pak C Sham; Jim van Os; Cathryn M Lewis; Michael Lynskey; Craig Morgan; Robin M Murray Journal: Lancet Psychiatry Date: 2019-03-19 Impact factor: 77.056